New therapeutic opportunities for women with low-grade serous ovarian cancer.

Moujaber, Tania; Balleine, Rosemary L; Gao, Bo; Madsen, Ida; Harnett, Paul R; DeFazio, Anna

Moujaber, Tania; Balleine, Rosemary L; Gao, Bo; Madsen, Ida; Harnett, Paul R; DeFazio, Anna.

Afiliação

Moujaber T; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
Balleine RL; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Gao B; Crown Princess Mary Cancer Centre, Westmead Hospital, Western Sydney Local Health District, New South Wales, Australia.
Madsen I; Blacktown Cancer and Haematology Centre, Blacktown Hospital, Western Sydney Local Health District, New South Wales, Australia.
Harnett PR; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
DeFazio A; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

Endocr Relat Cancer ; 29(1): R1-R16, 2021 11 11.

Article em En | MEDLINE | ID: mdl-34636747

Assuntos

Cistadenocarcinoma Seroso; Neoplasias Ovarianas; Neoplasias Peritoneais; Carcinoma Epitelial do Ovário; Cistadenocarcinoma Seroso/tratamento farmacológico; Feminino; Humanos; Gradação de Tumores; Neoplasias Ovarianas/metabolismo; Inibidores de Proteínas Quinases/uso terapêutico

Palavras-chave

MAPK pathway inhibitors; chemotherapy; endocrine therapy; low-grade serous carcinoma; ovarian cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Peritoneais / Cistadenocarcinoma Seroso Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Endocr Relat Cancer Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google